Gregoriou O, Vitoratos N, Papadias C, Gargaropoulos A, Konidaris S, Giannopoulos V, Chryssicopoulos A
Second Department of Obstetrics and Gynecology, University of Athens, Areteion Hospital, Greece.
Int J Fertil Womens Med. 1997 Sep-Oct;42(5):301-5.
To evaluate the efficacy of terazosin, an alpha-blocker, for the treatment of idiopathic oligozoospermia.
Thirty couples with infertility whose only detectable abnormality was male idiopathic subfertility entered the study. The diagnosis of idiopathic subfertility in all males studied, aged 26 to 38 years (mean 28.2 years), was confirmed after exclusion of any iatrogenic, systemic, congenital, infectious, autoimmune or endocrinological cause. In order to start with a baseline value before the study, at least three semen samples were evaluated in accordance with the WHO recommendation. Before initiation of treatment, blood samples were drawn for measurement of FSH, LH, testosterone, prolactin, dihydrotestosterone, and estradiol. Fifteen randomly selected patients (Group A) received 2 mg/d of alpha-blocker (terazosin), while another 15 (Group B) were administered an identically packed placebo tablet. Both groups received therapy for 6 months.
The mean seminal volume changed insignificantly between the two groups (4.15 +/- 1.95 vs. 4.10 +/- 1.95). There was a statistically significant increase of the sperm concentration in patients who received the alpha-blocker compared to those receiving placebo (24.76 +/- 9.45 vs. 13.15 +/- 11.55 millions/mL; P < .001). No improvement of the mean percentage of abnormal spermatozoa was observed in the treated patients, nor a statistically significant difference of sperm motility in the treated group compared to the placebo group. Side effects were not observed in the patients receiving terazosin treatment, or were so minimal that therapy was continued. The pregnancy rates did not differ between the two groups to a statistically significant degree.
The administration of terazosin to patients with idiopathic oligozoospermia has a demonstrably positive effect, especially on sperm concentration.
评估α受体阻滞剂特拉唑嗪治疗特发性少精子症的疗效。
30对不育夫妇进入本研究，其唯一可检测到的异常为男性特发性亚生育力。所有研究男性年龄在26至38岁（平均28.2岁），在排除任何医源性、全身性、先天性、感染性、自身免疫性或内分泌性病因后，确诊为特发性亚生育力。为在研究前获得基线值，根据世界卫生组织的建议，至少评估三份精液样本。在开始治疗前，采集血样以检测促卵泡生成素（FSH）、促黄体生成素（LH）、睾酮、催乳素、双氢睾酮和雌二醇。15名随机选择的患者（A组）接受2毫克/天的α受体阻滞剂（特拉唑嗪）治疗，另外15名（B组）服用包装相同的安慰剂片。两组均接受6个月的治疗。
两组间平均精液量变化不显著（4.15±1.95 vs. 4.10±1.95）。与接受安慰剂的患者相比，接受α受体阻滞剂治疗的患者精子浓度有统计学显著增加（24.76±9.45 vs. 13.15±11.55百万/毫升；P<.001）。治疗患者的异常精子平均百分比未改善，治疗组与安慰剂组相比精子活力也无统计学显著差异。接受特拉唑嗪治疗的患者未观察到副作用，或副作用极小以至于治疗得以继续。两组间妊娠率无统计学显著差异。
给特发性少精子症患者服用特拉唑嗪有明显的积极效果，尤其是对精子浓度。
